Cryo-Cell International Inc
AMEX:CCEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (6.5), the stock would be worth $3.95 (13% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.7 | $3.5 |
0%
|
| 3-Year Average | 6.5 | $3.95 |
+13%
|
| 5-Year Average | 10.8 | $6.56 |
+88%
|
| Industry Average | 21.8 | $13.3 |
+280%
|
| Country Average | 21.9 | $13.33 |
+281%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
C
|
Cryo-Cell International Inc
AMEX:CCEL
|
28.2m USD | 5.7 | -11.6 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
104.3B USD | 12.3 | 59 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
72.9B EUR | 12.6 | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
74.5B USD | 0 | 12.5 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.2B EUR | -25.1 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.4B EUR | 13.9 | 22.8 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.4B USD | 23.7 | 21 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21B USD | 627.8 | 24 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 6.7 | 11 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.4B USD | 69.1 | -27.5 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 6 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Cryo-Cell International Inc
Glance View
Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 83 full-time employees. The firm operates through three segments: The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use; the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells, and the cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives and other related healthcare professionals. The Company, in combination with its global affiliates, stores approximately 500,000 cord blood and cord tissue specimens around the world for the benefit of newborn babies and possibly other members of their families. Its processing and storage of specimens is handled from its facility in Oldsmar, Florida.
